CERT vs CRL
CERT: Certara utilizes proprietary biosimulation software and expert-led AI to help pharmaceutical companies optimize drug development and increase the probability of regulatory approval. CRL: A global contract research organization providing non-clinical drug development services, research models, and manufacturing solutions across discovery, safety assessment, and biologics testing.
Side-by-side fundamentals
| Metric | CERT | CRL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.89 | $218.70 | |
| Market cap as of 2026-07-23 | $1.1B | $10.6B | |
| PEG as of 2026-07-23 | -0.15 | -0.12 | CERT lower |
| Net margin as of 2026-07-23 | -3.6% | -4.6% | CERT higher |
| Gross margin as of 2026-07-23 | +61.6% | +34.5% | CERT higher |
| Operating margin as of 2026-07-23 | +2.2% | +1.8% | CERT higher |
| ROE as of 2026-07-23 | -1.4% | -5.7% | CERT higher |
| ROA as of 2026-07-23 | -1.0% | -2.5% | CERT higher |
| Debt / equity as of 2026-07-23 | 0.29 | 0.91 | CERT lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.4% | +0.1% | CERT higher |
| Revenue CAGR (3y) SEC XBRL | +7.7% | +0.3% | CERT higher |
| Beta as of 2026-07-23 | 1.42 | 1.38 | |
| 1-year return as of 2026-07-22 close | -32.4% | +33.9% | CRL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.